Open AccessGefitinib for asymptomatic brain metastasis from advanced non‐small cell lung cancer: Report of a favourable outcome
Author(s) -
Liu WenYang,
Liu YuTao,
Yang Lin,
Zhang Ye,
Liu Peng,
Wang Yan,
Hui ZhouGuang
Publication year - 2016
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12335
Subject(s) - medicine , gefitinib , brain metastasis , asymptomatic , oncology , lung cancer , metastasis , cancer , epidermal growth factor receptor
Brain metastasis ( BM ) is common in patients with non‐small cell lung cancer ( NSCLC ). Although epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors ( TKIs ) have now been included as standard treatment options for NSCLC harboring EGFR ‐activating mutations, only a few prospective reports demonstrate the efficacy of these agents in a BM setting. We report a case of a patient with advanced NSCLC , in which oral gefitinib documented a significant antitumor effect on parallel progression of extracranial lesion and BM occurred during chemotherapy.